We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current CGEM market cap is 464.45M. The company's latest EPS is USD -2.8363 and P/E is -2.77.
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -42.99M | -50.03M | -48.86M | -55.05M | -55M |
| Net Income | -37.15M | -42.03M | -40.56M | -47.65M | -48.5M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 18.94M | 0 | 0 | 0 |
| Operating Income | -60.34M | -67.95M | -132.14M | -191.09M | -196.92M |
| Net Income | -51.8M | -65.57M | 111.21M | -153.16M | -167.38M |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 449.43M | 681.22M | 653.25M | 621.82M | 579.68M |
| Total Liabilities | 23.77M | 25M | 25.39M | 31.5M | 27.84M |
| Total Equity | 425.67M | 656.22M | 627.86M | 590.33M | 551.84M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 214.71M | 437.19M | 561.12M | 484.18M | 621.82M |
| Total Liabilities | 14.39M | 11.81M | 26.09M | 30.29M | 31.5M |
| Total Equity | -76.34M | 425.37M | 535.03M | 453.9M | 590.33M |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -38.25M | -74.54M | -108.68M | -145.3M | -43.16M |
| Investing | 12.96M | -172.16M | -152.28M | -136.31M | 36.81M |
| Financing | 1.09M | 263.28M | 264.61M | 266.19M | N/A |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -29.77M | -43.43M | -126.66M | -134.33M | -145.3M |
| Investing | -5.42M | -333.78M | 248.98M | 35.81M | -136.31M |
| Financing | 140.14M | 268.78M | -25.93M | 40.75M | 266.19M |
| Market Cap | 464.45M |
| Price to Earnings Ratio | -2.77 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 5.6 |
| Price to Book Ratio | 0.79 |
| Dividend Yield | - |
| Shares Outstanding | 59.01M |
| Average Volume (1 week) | 298.49k |
| Average Volume (1 Month) | 375.15k |
| 52 Week Change | -52.96% |
| 52 Week High | 21.01 |
| 52 Week Low | 6.85 |
| Spread (Intraday) | 2.86 (28.21%) |
| Company Name | Cullinan Therapeutics Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.cullinantherapeutics.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
